(NASDAQ: CDTX) Cidara Therapeutics's forecast annual revenue growth rate of 30.35% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.92%.
Cidara Therapeutics's revenue in 2024 is $63,905,000.On average, 1 Wall Street analysts forecast CDTX's revenue for 2024 to be $127,318,470, with the lowest CDTX revenue forecast at $127,318,470, and the highest CDTX revenue forecast at $127,318,470. On average, 1 Wall Street analysts forecast CDTX's revenue for 2025 to be $488,882,855, with the lowest CDTX revenue forecast at $488,882,855, and the highest CDTX revenue forecast at $488,882,855.
In 2026, CDTX is forecast to generate $604,614,478 in revenue, with the lowest revenue forecast at $604,614,478 and the highest revenue forecast at $604,614,478.